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Severe weight loss and debilitative wasting of lean body mass frequently
complicate the treatment of patients suffering from malignancy or chronic
infection . Termed cachexia, this syndrome of anorexia, anemia, and weakness
further increases cancer mortality; some data indicate that as many as 30% of
cancer patients die from cachexia, rather than tumor burden (1-3) . The severity
of cachexia may be unrelated to tumor size or parasite load, and profound
wasting has been observed in patients with tumor burdens of only 0.01-5.0%
body mass (4). If not reversed, cachexia-associated derangements of homeostasis
lead to immunological deficiencies, organ failure, and multiple metabolic abnor-
malities . While it is clear that a variety of mechanisms participate in the patho-
genesis of cachexia, and that cachexia adversely affects prognosis, the etiology
of this syndrome is not known .
For a number of years we have been searching for endogenous, humoral
mediators of cachexia, beginning with the characterization of metabolic changes
in trypanosome-infected rabbits that develop profound cachexia and lose up to
50% of lean body mass within weeks . In later stages of disease a paradoxical
increase in circulating triglycerides occurs, attributable to systemic suppression
of lipoprotein lipase (LPL)t (5) . A bacterial LPS-inducible serum factor which
suppresses LPL in mice, and several other key lipogenicenzymes in the adipocyte
cell line 3T3-L1, was isolated and named cachectin (6, 7) . Cachectin evokes a
state of cellular cachexia by suppressing the expression of several mRNAs
encoding essential lipogenic enzymes (8, 9). Myocytes also show changes in
cellular metabolism after exposure to cachectin in vitro, including a prompt
decrease in resting transmembrane potential difference and depletion of intra-
cellular glycogen stores with increased lactate efflux, and a later increase in
hexose transporters (10, 11). It has been suggested that cachectin may play a
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central role in cachexia, and the administration of conditioned medium contain-
ing cachectin from LPS-induced macrophages induces anorexia and weight loss
in mice (12).
Independent genetic sequence analysis subsequently proved the identity of
cachectin and tumor necrosis factor (TNF) (13-15). The availability of recom-
binant human cachectin allows the spectrum of biological responses attributable
to this hormone to be characterized in detail. High doses of cachectin are
extremelytoxic, andacute intravenous administration inducescatabolic hormone
release, tissue injury, and fatal shock(I6, 17). Moreover, anticachectin antibodies
can passively protect animals against shock and death during endotoxemia (18)
or Escherichia coli bacteremia (19), suggesting that cachectin is the principal
mediator ofacuteresponses to Gram-negative bacterial invasion. Recent evidence
suggests that chronic low-dose treatment with cachectin is also toxic, causing
anorexia and weight loss (20). Cachectin-induced cachexia was elegantly dem-
onstrated by Oliff et al. (21), who report severe weight loss and increased
mortality in mice bearing transgenic tumors that persistently secrete human
cachectin.
The present report gives evidence that chronic administration of sublethal
doses of recombinant human cachectin to rats induces a syndrome strikingly
similar to disease-associated cachexia. Anorexia, weight loss, depletion ofwhole-
body protein and lipid stores, reduction of red blood cell mass, leukocytosis, and
tissue inflammation were induced by twice daily injections given for 7-10 d.
Sham-injected pair-fed controls lost weight but did not develop the specific
manifestationsofcachectintoxicity and cachexia. Thesedata suggestthat chronic
exposure to cachectin, as likely occurs during cancer or chronic disease, partici-
pates in the metabolic and hematologic responses of cachexia.
Materials and Methods
Cachectin.
￿
Recombinant human cachectin was expressed in a yeast system, prepared
as previously described, andwas the generous gift ofthe Chiron Corporation, Emeryville,
CA (16). The purified protein wasdiluted in 5 mM PBS (pH 7.4) to a final concentration
of 2 mg/ml and was filter sterilized. The endotoxin/LPS content was <25 ng LPS/mg
cachectin, as assayed by the Limulus amebocyte lysate test (M. A. Bioproducts, Walkers-
ville, MD).
Monoclonal Antibody.
￿
Murine monoclonal anti-recombinant human cachectin antibody
purified from ascites fluid from tumors of American Type Culture Collection (Rockville,
MD) cell line HB 9228 was a generous gift of the Chiron Corporation. F(ab')2 fragments
were prepared by incubation with pepsin (25 ug/ml) in citrate buffer (pH 3.5) for 8 h at
37°C according to previously described methods (22). The appearance of F(ab')2 was
monitored by pHAST gel electrophoresis; the final product was purified using mono-Q
column chromatography and dialyzed exhaustively against normal saline. Purified F(ab')2
completely neutralized at least 50 ng/ml of recombinant human cachectin (10' U/mg) at
an antibody concentration of 10 Ag/ml as assayed in the standard L929 cell cytotoxicity
assay (23).
Endotoxin. LPS (E. coli strain 0127:138, Difco Laboratories Inc., Detroit, MI) was
diluted in PBS (pH 7.4) to a final concentration of 0.1 ng/ml.
Experimental Protocol.
￿
Female Sprague-Dawley rats weighing 250-300 g were housed
in individual metabolic cages with 12-h light-dark cycles, and provided water and Purina
Rat Chow ad libitum for at least 7 d before use. All animals were weighed daily at 8 :00
a.m. when total 24 h food and water intake were recorded. Animals were studied in
groups of 5-10, and during the study periods (7-10 d) were given twice daily (9:00 a .m.TRACEY ET AL.
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and 8:00 p.m.) intraperitoneal injections of recombinant human cachectin diluted in 0.5
ml of 5 mM PBS (pH 7.4). Previous studies estimated the LD50 for recombinant human
cachectin in Sprague-Dawley rats at 700 ,ug/kg (16); we used a sublethal dose (250 wg/kg)
for the present experiments. To generate an appropriate control population, control and
pair-fed control animals were handled similarly except that human albumin, instead of
cachectin, was injected at similar doses. Pair-fed control animals were allowed access to
only the average quantity of food consumed by rats of the cachectin-treated group (gram
of food/kilogram body weight) during the previous 24 h.
Hematocrits were determined from 10-Al samples of freely flowing blood from a tail
vein puncture. At the completion of any study period complete blood count was deter-
mined from intracardiac blood samples; animals were killed by pentobarbital overdose
administered via the inferior vena cava. Necropsy was performed, and tissue sections from
vital organs were obtained for histopathological analysis.
Body Composition Analysis.
￿
Whole-body content of water, fat, and protein were deter-
mined by previously described methods (24). Whole carcasses were cut into 2.5 X 2.5 cm
pieces, autoclaved to soften the pelts (210°C for 20 min), then homogenized in a blender
with 500 ml of distilled water. Aliquots of the homogenized solution were weighed,
frozen, and lyophilized (200 millitorr) for 1 wk. Total carcass water was calculated by
subtracting total dry weight from total carcass weight. Total carcass fat content was
determined gravimetrically by exhaustive extraction of a 2 g lyophilized sample with 2:1
chloroform/methanol (24). Total nitrogen in the lyophilized sample was determined by
Dumas methodology with an automated elemental analyzer (model 240; Perkin-Elmer
Corp., Norwalk, CT); a factor of 6.25 was used to convert total body nitrogen to total
body protein.
Estimation of Blood Volume.
￿
Total circulating blood volume was estimated at the
completion of a 10-d experimental period by dilution of "Cr-labeled RBCs according to
a modification of previously described methods (25). Heparinized syngeneic donor blood
(18 ml) was incubated with 'Cr (2 mCi) for 45 min at 25°C. The mixture was centrifuged
(1,000 g, 20 min) and the cell pellets were rinsed with two volumes of 0.9% saline. The
cells were then resuspended to the original blood volume in 0.9% saline. Recipient rats
were anesthetized with pentobarbital and the left carotid artery was cannulated with
polyethylene tubing (PE-50, outside diameter 0.965 mm; Becton Dickinson, Inc., Parsip-
pany, NJ). "Cr-labeled donor blood (1 ml) was injected into the arterial cannula at time
0; at t = 30 min, 500 11 of blood was withdrawn through the cannula and discarded; then,
20 u1 of blood was sampled in a graduated capillary tube and sample radioactivity was
quantitated in a gamma counter (counting error <2%). Blood volume was estimated by
dividing the counts per minute injected by counts per minute per milliliter of arterial
blood sampled at t = 30 (25). RBC mass was then calculated by multiplying the estimated
blood volume by percent packed cells (hematocrit) and by 1 .056 (specific gravity of rat
blood) (25), and RBC mass was expressed as a percentage of body weight.
Histopathology.
￿
Tissue specimens obtained from vital organs at necropsy were fixed
with 10% formaldehyde in PBS for 5 d. Tissue sections were stained with hematoxylin
and eosin (H&E) for histopathologic analysis.
Statistics.
￿
All data are presented as mean f SE. Comparison between groups was made
using Student's t test for unpaired observations or by one-way analysis of variance where
appropriate. p < 0.05 was considered statistically significant.
Results
Food Intake and Weight Changes During Cachectin Administration.
￿
No animals
died during the course of chronic administration of recombinant human cach-
ectin at a dose of 250 ug/kg given intraperitoneally twice daily. This cachectin
dosage induced a significant reduction of food intake as compared with controls
receiving albumin injections (Fig. 1). Cachectin-induced anorexia was abolished
if the animals were injected daily with anticachectin antibodies (10 mg/kg
administered intraperitoneally, once daily).1214 CACHECTIN INDUCES CACHEXIA, ANEMIA, AND INFLAMMATION
120
a 100
° u
0
0
d
0 a
so
60
40
20
0
FIGURE 1 .
￿
Anorexia induced by the chronic
administration of cachectin . Rats were ran-
domly divided into separate groups and re-
ceived twice daily injections of either albumin
(controls, 250 14g/kg, n = 6) (circles), or cach-
ectin (250 tag/kg, n = 5) (squares) for 8 d . A
separate group (n = 6) receiving cachectin twice
daily also was injected with anticachectin anti-
bodies (10 mg/kg) each morning (triangles).
Food intake for each group is shown as the
percentage of food intake in albumin-injected
controls ; all studies carried out in metabolic
cages . *p < 0.05 as compared with albumin-
injected controls.
FIGURE 2.
￿
Weight loss associated with cachec-
tin-induced anorexia. The mean change in body
weight over the 8-d study is depicted for the
following experimental groups : albumin-injected
controls (250 Ag/kg, twice daily, n = 6) (stippled
bars) ; cachectin (250 t<g/kg, twice daily, n = 5)
(angled bars) ; antibody-treated cachectin-injected
rats (n = 6) (crosshatched bars); and pair-fed, al-
bumin-injected controls (250 lAg/kg, twice daily,
n = 6) (horizontal bars).
At the end of the study period, the cachectin-treated animals, which had
consumed only 60% ofthealbumin-injected controls' food intake, had statistically
significant weight loss (p < 0.05 as compared with albumin-injected controls)
(Fig . 2) . Weight losses by cachectin-injected rats did not differ significantly from
those of pair-fed controls . Daily administration of anticachectin antibodies to
cachectin-treated animals protected against weight loss as well as anorexia . A
separate group of animals were injected with endotoxin/LPS (10 ng/kg, twice
daily) ; neither anorexia nor weight loss was observed with this dose of endotoxin
given for 10 d (data not shown) .
In some experiments, we observed a loss of the anorectic effect of chronic
cachectin administration after 3-5 d. Anorexia was reinstituted when the dose
of cachectin was increased to 500 ug/kg . By the eighth or ninth day, a repeat
tolerance to cachectin was similarly counteracted by redoubling the dose of
administered cachectin (to 1,000 wg/kg) . The nature of this tachyphylaxis is not
understood at present . To adjust for this response in subsequent experiments,
we routinely titrated increasing cachectin doses to maintain food intake at ^-60%
of the albumin control group intake . No differences were observed between the
animals that did or did not develop tachyphylaxis for any of the parameters
described below .
Body Composition Analysis.
￿
The body compositions of normal and pair-fed
control rats (Table I) agree closely with previous reportsfrom other laboratories*p< 0.05 vs. controls .
$p< 0.05 vs. pair-fed .
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TABLE I
Body Composition After Chronic Cachectin Administration (Mean±SE)
FIGURE 3 . Anemia induced by chronic
cachectin administration . Packed cell vol-
ume (hematocrit) was measured on the days
indicated for three experimental groups:
albumin-injected controls (250 rug albu-
min/kg, twice daily) allowed to feed ad libi-
tum (n= 20) (stippled bar), pair-fedalbumin-
injected (250 jug albumin/kg, twice daily)
controls (n =20) (horizontal bars), and cach-
ectin-injected (250,ug cachectin/kg, n= 18)
(angled bars) . *p < 0.05 as compared with
albumin-injected freely feeding or pair-fed
controls .
(24) . As wouldbe expected during the normal protein-sparing response to partial
starvation of the pair-fed controls (food consumption reduced to -60% of
albumin controls), body protein was spared while body fat was significantly
depleted . Chronic cachectin administration, however, was associated with a
depletion of whole-body protein stores which differed significantly from the
simple starvation-associated changes . Fat stores were diminished in the cachectin-
treated group, but to a lesser degree than in pair-fed controls . Slight increases
ofwhole-body water were observed in the pair-fed and cachectin-treated groups,
but these changes were not statistically significant as compared with controls .
Anemia andDecreasedRBCMass.
￿
A significant anemia developed in cachectin-
treated animals, but not in the albumin-treated controls or pair-fed controls (Fig .
3) . Hematocrits fell within 3 d and continued to decline throughout the study
period . There was no evidence of grosshemorrhage or external blood loss either
during the experiment or at necropsy,andno microscopic blood loss was detected
in urine or stool .
To determine whether the decreased hematocritwas due to relative expansion
of the plasma volume or to diminished RBC mass, blood volume was estimated
at the end of the experimental period by dilution of "Cr-labeled RBCs (Table
II) . Blood volumes in the cachectin group were not significantly different than
in sham-injected or pair-fed control groups. Thus, when corrected for the
diminished packed cell volume, RBC mass was significantly decreased in the
anemic cachectin-treated group . Cachectin-induced anemia was not associated
with an increased number of circulating reticulocytes (1 .2 ± 0.3%) compared
with the control group (2.1 ± 0.3%) . A marked leukocytosis was observed after
cachectin administration but not in controls or pair-fed animals (Table II) .
n Liverweight Heart weight Body water Body fat Body protein
Controls 6 3 .32 ± 0.06 0.32 ± 0.01 63.6 ± 0.6 11.9 ± 0.5 22.7 ± 0.9
Pair-fed 6 2.88±0.05 0.34±0.01 68.7±0.6 6.0±0.4* 23.4±0 .7
Cachectin 5 5.40 ± 0.16*,$ 0.39 ± 0.01*, :t 65.0 ± 1 .5 8.3 ± 0.5$ 19.8 ± 0.8*,$1216 CACHECTIN INDUCES CACHEXIA, ANEMIA, AND INFLAMMATION
TABLE II
Blood Volume and Complete Blood Count after Chronic CachectinAdministration (Mean ± SE)
(6)
￿
(6)
￿
(10)
￿
(10)
* Numbers in parentheses represent nfor the groupindicated.
$p <0.01 vs. controls and pair-fed.
Pathologic Changes.
￿
Cachectin-treated animals exhibited gross pathology not
observed in control or pair-fed rats. The mesenteric adipose of the cachectin-
treated animals was invariably darkened and thickened, changes rarely observed
in the controls injected with albumin. Chronic exposure to cachectin also led to
organ-specific liver and heart weight increases (Table 1). Although spleen weights
were increased somewhat, the changes were not statistically significant as com-
pared with albumin-controls or pair-fed controls (data not shown).
Microscopic examination revealed a number of pathological alterations in
tissues from rats injected with cachectin. The most prominent changes were in
omentum, spleen, liver, and heart.
Omentum.
￿
While a mild degree of omental inflammation was present in the
controls, there was extensive evidence of a more severe inflammatory reaction
in omental tissue from the cachectin-injected animals (Fig. 4). The histologic
changes consisted of infiltration by chronic inflammatory cells, proliferation of
small blood vessels, and reactive mesothelial hyperplasia. The cellular reaction
was pleomorphic, but consisted largely of lymphocytes and macrophages with
occasional clusters of neutrophils. When the inflammatory reaction was scored
semiquantitatively (from 0-4), the severity of the reaction was scored as 3.2+ in
five cachectin-treated animals, 0.8+ in three normal controls, and 1+ in four
control pair-fed animals.
Spleen.
￿
Cachectin-treated animals exhibited depletion of lymphocytes from
the marginal zone of the lymphoid follicles (Fig. 4). Although the severity of
such depletion varied, it was obvious in all animals as compared with albumin-
treated or pair-fed controls.
Liver.
￿
The livers of animals receiving cachectin exhibited proliferation of
small bile ducts in the portal tracts, surrounded by a pleomorphic mononuclear
infiltration (Fig. 4). In some sections focal hepatic parenchymal cell necrosis was
observed. Small foci of extramedullary hematopoiesis were also present.
Heart.
￿
Thehearts ofcachectin-treated animalsexhibiteda distinct endocardia
and subendocardial lesion not present in controls. There was focal infiltration of
subendocardium by chronic inflammatory cells (Fig. 4), associated with pro-
nounced hypertrophy and hyperplasia of intimal endothelial cells and subintimal
fibroblasts. There was also focal myocardial cell hypereosinophilia and necrosis.
Cachectin
dose (b.i.d.)
mg/kg
Bloodvolume
(percent body
weight)
RBC mass
(percent body
weight)
Hemoglobin
g/dL
Leukocytes
x 10-3/MMI
Controls 0 6.30 ± 0.12 2.84 t 0.05 13 .5 ± 0.9 5.8 ± 1.2
(6)* (6) (15) (15)
Pair-fed 0 6.69 ± 0.12 3.14 ± 0.06 13 .8 ± 0.4 5.1 ± 1.2
(6) (6) (8) (8)
Cachectin 0.25 6.28 ± 0.28 1.76 ± 0.08$ 7.9 t 0.6$ 14.7 ± 1.5$TRACEY ET AL .
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The areas around capillary muscles were most obviously affected. There was no
evidence ofadherent thrombi.
Other Organs.
￿
The bone marrow from the controls was normocellular. The
marrow of the anemic, cachectin-treated group was not significantly different
from controls and there was no evidence of increased cellularity. The kidneys
were not appreciably different in cachectin-treated animals as compared with
controls. The lungs of the cachectin-exposed animals showed foci of interstitial
inflammation, but such foci were also present in control animals. It was not
possible to regularly differentiate tissues of animals from each group by exami-
nation ofthe lung alone.
Discussion
The present data indicate that chronic exposure to cachectin is capable of
inducing cachexia. Anorexia and weight loss after cachectin administration were
associated with the depletion of whole-body protein and lipid stores. Moreover,
these studies have identified other cachectin-specific responses, such as anemia,
leukocytosis, and tissue inflammatory changes, which were independent of re-
duced food intake (as determined by comparison to pair-fed controls). These
deleterious changes are similar to derangements occurring in malignancy- or
infection-associated cachexia, suggesting that cachectin may well contribute to
cachexia in some disease states.
Persistent exposure to cachectin prevented the adaptive protein conservation
response usually observed during nonstressed partial starvation. As would be
expected from previous animal and human studies (reviewed in reference 26),
food-restricted controls preferentially deplete lipid stores to meet daily energy
requirements (Table II). During cachectin-induced anorexia, however, endoge-
nous protein stores are depleted in a manner quantitatively similar to that noted
in disease-related cachexia (26). While previous investigators have reported that
cachectin does not directly induce protein breakdown in isolated skeletal muscle
in vitro (27), the present data suggest that net whole-body protein erosion is
enhanced by the systemic administration ofcachectin.
The present data do not clarify to what degree cachectin-induced cachexia is
mediated via enhanced whole-body energy expenditure, centrally mediated
anorexia, or altered peripheral metabolism. Cachectin is known to induce the
release of IL-1 from endothelial cells and macrophages (28, 29), and IL-1 may
cause anorexia (30). IL-1 is known to induce catabolic hormone release (ACTH
and corticosterone), and these factors in turn might contribute to accelerated
catabolism (31, 32). In addition, cachectin may also induce increased levels of
glucagon, cortisol, and the catecholamines (17). While these changes in hormonal
status may be indirectly stimulated by cachectin, direct cellular injury to gastroin-
testinal epithelial and endothelial cells has been observed after injection of a
single sublethal dose of cachectin (16, 33). Further investigation is therefore
needed to delineate the multiple contributory mechanisms ofcachectin to cach-
exia.
Tolerance developed to the anorexigenic effects of recombinant human cach-
ectin during repeated intraperitoneal injections in the rat, and this may explain
why previous investigators have failed to observe sustained cachexia during1222 CACHECTIN INDUCES CACHEXIA, ANEMIA, AND INFLAMMATION
cachectin injection protocols (34, 35). The biochemical mechanisms involved in
this tachyphylaxis remain unclear. Tolerance to other hormones (e.g., insulin,
IL-1) has been attributed to altered intracellular second messenger responses,
downregulation of plasma membrane receptors, and the appearance of circulat-
ing inhibitors, antibodies, or specific carrier proteins. Mice injected with endo-
toxin-activated conditioned medium from murine macrophages also exhibit
tolerance to the anorexigenic effect when given at low doses, but not at higher
doses (12) . Oliff et al. (21) recently observed severe cachexia in nude mice
bearing tumors secreting recombinant human cachectin/TNF, but not in controls
bearing non-cachectin-secreting tumors. They did not observe tachyphylaxis in
a carefully done study, and postulated that the continual presence of cachectin
in the circulation may be necessary to induce persistent cachexia. Further studies
of the kinetics of cachectin appearance and clearance during cachexia are needed
to better understand the role of this factor in both experimental models and
disease states.
Macrophage products have been implicated as mediators of the anemia asso-
ciated with malignancy or chronic inflammation, but the etiology of decreased
RBC mass is not fully understood (36, 37). Cachectin/TNF inhibits hematopoietic
precursor cell proliferation, and directly inhibits the expression of erythroid
burst-forming units in vitro (38-40). Cachectin/TNF is also capable, however,
of stimulating the production of granulocyte/monocyte colony-stimulating fac-
tor, and can directly induce the differentiation of hematopoietic stem cells (41-
43). Thus, while cachectin might influence hematopoiesis through both stimu-
latory and inhibitory activities, the present study demonstrates that the net effect
ofchronic cachectin exposure in vivo is hypoproductive anemia. Anemia has also
been observed after TNF infusions in cancer-bearing man (44), suggesting the
importance of this response in human disease.
Leukocytosis is a hallmark of chronic inflammation and in part represents the
mobilization of leukocytes necessary to promote tissue-specific host defense
mechanisms and inflammation. A large body of evidence supports previous
suggestions that cachectin/TNF is a central mediator of inflammation: in addition
to being a potent pyrogen, cachectin is capable of inducing PGE-2 and collagenase
release, activating leukocytes, stimulating expression of activation antigens on
endothelium, and enhancing leukocyte chemokinetics (reviewed in references
45, 46). The elevated numbers of circulating leukocytes after chronic cachectin
exposure in the present study likely reflect chronic systemic inflammation and
toxicity. It seems probable that other humoral products of the inflammatory
response participate as mediators of the wasting cachectic state. However, the
multiple systemic derangements ofhomeostasis induced by cachectin are striking,
and suggest a means of therapeutic intervention by antagonism of this proximal
mediator.
Previously we have shown that cachectin is capable of inducing acute hypody-
namic shock and severe tissue injury in normal animals (16, 17). The pattern of
tissue inflammation after cardiovascular collapse and shock is different, however,
from the present observations after chronic administration of cachectin/TNF.
After acute cachectin-induced shock, critical organ injury is very similar to acute
lethal endotoxemic lesions and primarily involves the kidneys, lungs, adrenals,TRACEY ET AL .
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and gastrointestinal tract (16, 17) . After chronic injections ofcachectin, however,
the kidneys and lungs were relatively spared, and significant abnormalities in the
liver, heart, spleen, and omental adipose were observed . Periportal inflammation
and increased liver weights were observed in cachectin-treated animals . This
latter observation is characteristic of other cachexia syndromes, and in the
present study is likely due to several factors . Extramedullary hematopoiesis
typically occurs in rats during anemia, and could contribute to increased total
organ weight . Extensive inflammation with accumulation of inflammatory cells
and associated edema also contribute to increased organ weight. Since cachec-
tin/TNF also stimulates increased total liver protein synthesis and is capable of
directly stimulating increased acute phase protein biosynthesis (30, 47, 48), the
increased liver weights in the present study are consistent with observations in
other inflammatory states where hepatic parenchymal protein accrual likely
representsan adaptive acute phase response .
Cachectin-induced cardiac lesions have not been observed previously, but
other evidence implicates cachectin as a mediator ofcardiac dysfunction . Cardiac
output declines sharply after the infusion of cachectin in dogs, and the falling
cardiac output is not restored by either intravenous fluid administration or
significant elevations of circulating catecholamines (17) . Furthermore, cardiac
function is significantly improved during primate bacteremia by passive immu-
nization with anticachectin mAbs (19) . Specific alterations of skeletal muscle
resting membrane function and energy metabolism have also been observed in
response to cachectin infusion (10, 11) . The pathogenesis of the peculiar cach-
ectin-induced subendothelial inflammation is unclear .
Cachectin-induced depletion of the marginal zone of the splenic lymphoid
follicles has also not been previously observed . In normal rats, the marginal zone
consists largely ofB cells that express a variety of activation antigens . The specific
depletion of activated lymphocytes (Fig . 4) may represent mobilization of these
activated immunoresponsive cells as a part of cachectin-induced inflammatory
responses. Another interesting feature of splenic histology was the apparent
absence of blood forming units in the spleens of the cachectin-treated anemic
rats . The number of erythroid forming units in both hepatic and splenic tissue
is characteristically increased during anemia in rodents . Whereas some compen-
satory extramedullary hematopoiesis occurs in the liver after cachectin-induced
anemia, the lack of a parallel splenic response may contribute to thedevelopment
of anemia .
Blood monocytes obtained from cancer patients show enhanced cachectin
responses (49), and several laboratories have reported increased serum cachec-
tin/TNF levels in association with a variety of diseases including malaria and
Leishmaniasis (50), meningococcal septicemia (51), acute renal allograft rejection
(52), prolonged critical illness and sepsis (53) ; and in volunteer subjects given
small doses of intravenous endotoxin (54) . Serum cachectin levels during some
human cachectic states may well be below the limits of detection for currently
available assays, and further study is needed to clarify the role of endogenous
cachectin production in the development of cachexia in man .
The identification of a host factor that is sufficient to induce cachexia, anemia,
leukocytosis, and inflammation in a variety of tissues advances our understanding1224 CACHECTIN INDUCES CACHEXIA, ANEMIA, AND INFLAMMATION
of the systemic responses to invasion and injury . Cachectin-mediated anorexia
and alterations ofcellular metabolism may contribute to many ofthe nutritional
features observed incancer cachexia, trauma, and inflammation . Since protection
against cachectin-induced cachexia is conferred by the administration ofantica-
chectin antibodies in this study, cachectin antagonists may be of use during the
nutritional therapy of some cachexia syndromes.
Summary
Cachexia is a potentially lethal syndrome of unknown etiology characterized
by anorexia, weight loss, and protein wasting that frequently complicates the
treatment of chronic inflammation and cancer. Cachectin/TNF was isolated
during the search for a humoral mediator of cachexia and found to stimulate
the breakdown of energy stores from adipocytes and myocytes in vitro, but the
chronic effects of the monokine in vivo are not known. Sublethal doses of
recombinant human cachectin administered twice daily for 7-10 d caused cach-
exia in rats, as evidenced by reduced food intake, weight loss, and depletion of
whole-body lipid and protein stores. Significant anemia is also observed and
found to be the result of decreased red blood cell mass, not expanded plasma
volume. Leukocytosis and histopathological evidence oftissue injury and inflam-
mation are observed in several organs, including omentum, liver, spleen, and
heart. These data suggest that the exposure of the normal host to cachectin is
capable of inducing a pathophysiological syndrome of cachexia, anemia, and
inflammation similar to that observed during inflammatory states or malignancy.
Receivedfor publication 9 November 1987.
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